Quantumup
Posted - 1 day ago
Citi (11/18/2024)🏁 $AKRO Buy/$65—FGF21RA Efruxifermin has shown compelling efficacy4 #MASH that's likely2support meaningful⬆️take; is likely2differentiate in cirrhotic MASH; is well-positioned ahead of the impending GLP-1 entrance in MASH,🎯g a different subset of pts: $iva $vktx $mdgl $etnb
ms1sd
Posted - 2 days ago
@Kingjake26 thoughts on $AKRO ?
ms1sd
Posted - 2 days ago
$AKRO Citi initiated coverage of Akero Therapeutics with a Buy rating and $65 price target. Akero is a clinical stage biotech developing efruxifermin, a novel FGF21 agonist, as a potential best-in-disease therapy for the treatment of metabolic dysfunction-associated steatohepatitis, the analyst tells investors in a research note. The firm says efruxifermin has demonstrated compelling efficacy for MASH with moderate to advanced fibrosis that is likely to support meaningful uptake, particularly for more severe patients, despite launching into an established market.
ms1sd
Posted - 2 days ago
$AKRO sorry...read last 4 posts from me, bottoms up!
ms1sd
Posted - 2 days ago
$AKRO "We believe that, taken together, the suite of presentations provides evidence supporting the consistent anti-fibrotic effects of EFX observed to date in the HARMONY trial as well as the the clinical activity and generally favorable safety profile of EFX in patients with precirrhotic MASH (F2-F3). The ongoing Phase 3 SYNCHRONY program is designed to confirm a favorable benefit-risk profile and support marketing applications for EFX for the treatment of MASH
ms1sd
Posted - 2 days ago
$AKRO The second poster presentation shows that 30% of participants receiving EFX 50mg for 96 weeks had almost complete reversal of MASH-related disease, as indicated by reversal of fibrosis to Fless than or equal to1, resolution of MASH, and normalization of liver fat content to less than or equal to5%, compared to 0% of participants on placebo. In addition, 100% of participants who received EFX 50mg for 96 weeks were categorized as "low risk of progressive MASH" by FibroScan-AST score. In contrast, 48% of participants receiving placebo remained at high or indeterminate risk of progressive MASH. Based on the same analyses, the extent of reversal of disease relative to placebo was smaller for participants receiving EFX 28mg than 50mg.
ms1sd
Posted - 2 days ago
$AKRO We believe these new analyses provide further evidence for the potential of EFX to be a differentiated therapy for MASH." One poster presents an orthogonal analysis of baseline, week 24, and week 96 liver biopsies from HARMONY by HistoIndex. This analysis corroborates the pattern of anti-fibrotic effects observed with conventional pathology after treatment with EFX for 24 or 96 weeks. Specifically, a quantitative analysis by qFibrosis across different zones of the liver revealed EFX-associated reductions in fibrosis primarily in the perisinusoidal and periportal zones that were sustained or expanded from weeks 24 through 96 for participants, regardless of baseline fibrosis stage.
ms1sd
Posted - 2 days ago
$AKRO Akero to showcase new analyses of Phase 2b HARMONY study at AASLD Akero Therapeutics announced results of analyses supporting the clinical activity of efruxifermin in metabolic dysfunction-associated steatohepatitis in one oral presentation and two late-breaking poster presentations at the 75th Annual American Association for the Study of Liver Diseases The Liver Meeting, held November 15-19, 2024, in San Diego. "The data to be presented at The Liver Meeting show that 96 weeks of treatment with EFX has the potential to drive substantial reversal of disease in patients living with pre-cirrhotic MASH," said Kitty Yale, chief development officer of Akero. "We are encouraged by consistent improvements observed across a number of clinically established markers of liver health and the corroboration of conventional histopathology assessments with Artificial Intelligence (AI)-based digital pathology.
ms1sd
Posted - 2 days ago
@Kingjake26 have you looked in $AKRO , yet? Curious as your thoughts, Jake.
MaverikIT
Posted - 3 days ago
@IsabellaDC @net0trader $FAT $AKRO
Joepool
Posted - 3 days ago
$AKRO Good play with rfk statements. He is against glp agonists taking out a big category of potential mash treatment drugs.
Ag_0018
Posted - 3 days ago
$AKRO
PeedyWeedy
Posted - 5 days ago
$AKRO Is data to be released on the 18th? What type of move is expected?
MaddisonCox
Posted - 5 days ago
😏🚀 MYNZ We know the date of the reverse split (RS) if there will be one, but possibly a Nasdaq extension will be granted. Last time it traded, 50 million and 19 million heavy shorts attacked. Now, it has huge credibility after the TMO partnership and the meeting. The company will decide by November 25th whether or not to do an RS based on Nasdaq's response. Anyway, after the RS, I'm not worried about what happens next. A $210 billion partner TMO signing a deal with a penny stock has never happened before. I will be loading heavy on Monday. This will go to the moon like the DRUG stock recently did. The price target (PT) is $50. The squeeze will be parabolic. $AKRO $SLNO
Market_Max
Posted - 1 week ago
$SGMT The imbeciles at Goldman Sachs are defending the $6 like their lives depends on it. Otherwise, this stock should be running wild like $ALGS is right now. I remember buying $ALGS at $12, $10 and $9. Just exited today at $20. This one is way way better than $ALGS. But for the shorting and distorting works of Goldman Sachs, this should be well over $20 right now and closer to the market cap of $AKRO.
All_just_a_game
Posted - 1 week ago
$AKRO $ETNB $VKTX $ALT Is the thesis that bone density loss is correlated to muscle mass loss? Not sure all the GLP trials are actually testing for bone density?
I know this is a red flag 🚩 for the FGF21 class. https://www.cnbc.com/amp/2024/11/12/amgen-stock-falls-on-weight-loss-drugs-bone-density-loss-data.html
robo84
Posted - 1 week ago
$ALT No stop here ...
The data tomorrow looks promising...hopefully it can keep up with or outperform the competition
$OCEA $AKRO
Ag_0018
Posted - 1 week ago
$AKRO $60 PT
Ag_0018
Posted - 1 week ago
$AKRO
Ag_0018
Posted - 1 week ago
$AKRO higher high? higher low... $40+ by end of the year
All_just_a_game
Posted - 1 week ago
$MDGL $ALT $VKTX $AKRO looks too young to step down to pursue “private endeavors”. One of these companies should snatch him up…Madrigal has a big dog CEO from Sanofi..so it would not be a CEO position if he went to MDGL…but the others…this would be a HUGE step up in CEO position. He probably wants to be CEO…
https://medwatch.com/News/Pharma___Biotech/article17612221.ece
Ag_0018
Posted - 1 week ago
$AKRO drop at the open and slowly climb up to close green
DonCorleone77
Posted - 1 week ago
$AKRO Akero Therapeutics reports Q3 EPS ($1.05), consensus (90c) "The third quarter of 2024 marked an important milestone for EFX with the first patient dosed in the Phase 3 SYNCHRONY Outcomes study," said Andrew Cheng, president and CEO. "With this advancement, all three of our Phase 3 studies are actively enrolling - furthering our assessment of the safety and efficacy of EFX and moving us closer to delivering a differentiated treatment option, if approved, to patients living with MASH."
Chance_Cr
Posted - 2 weeks ago
MYNZ moving +12.25% in PM and opening climbing up same with volume 🚀 All is buying, ready for the squeeze. HUGE PR drop incoming before the Nov 13 meeting, so compliance is coming, no RS needed. $AKRO $SLNO $VCEL
insiderbuyingselling
Posted - 2 weeks ago
$AKRO new insider selling: 50716 shares. http://insiderbuyingselling.com/?t=AKRO
insiderbuyingselling
Posted - 2 weeks ago
$AKRO new insider selling: 108366 shares. http://insiderbuyingselling.com/?t=AKRO
insiderbuyingselling
Posted - 2 weeks ago
$AKRO new insider selling: 20000 shares. http://insiderbuyingselling.com/?t=AKRO
Ag_0018
Posted - 2 weeks ago
$AKRO moving up with higher than usual volume, very Bullish
Ag_0018
Posted - 2 weeks ago
$AKRO my new PT is $60. We should have at a minimum half of Madrigals market cap
